Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal DiseasesReceptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases
- Other Titles
- Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases
- Authors
- 이은지; 박종훈
- Issue Date
- Dec-2013
- Publisher
- 한국유전체학회
- Keywords
- advanced glycosylation end-product receptor; kidney diseases; signal transduction
- Citation
- Genomics & Informatics, v.11, no.4, pp 224 - 229
- Pages
- 6
- Journal Title
- Genomics & Informatics
- Volume
- 11
- Number
- 4
- Start Page
- 224
- End Page
- 229
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/11452
- DOI
- 10.5808/GI.2013.11.4.224
- ISSN
- 1598-866X
2234-0742
- Abstract
- Receptor for advanced glycation endproducts (RAGE) is a multi-ligand receptor that is able to bind several different ligands,including advanced glycation endproducts, high-mobility group protein (B)1 (HMGB1), S-100 calcium-binding protein,amyloid-β-protein, Mac-1, and phosphatidylserine. Its interaction is engaged in critical cellular processes, such asinflammation, proliferation, apoptosis, autophagy, and migration, and dysregulation of RAGE and its ligands leads to thedevelopment of numerous human diseases. In this review, we summarize the signaling pathways regulated by RAGE and itsligands identified up to date and demonstrate the effects of hyper-activation of RAGE signals on human diseases, focusedmainly on renal disorders. Finally, we propose that RAGE and its ligands are the potential targets for the diagnosis,monitoring, and treatment of numerous renal diseases.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 이과대학 > 생명시스템학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.